Arrowhead Pharmaceuticals, Inc.

$56.55

$0.42(-0.73%)

Arrowhead Pharmaceuticals, Inc.

ARWR

$56.55

$0.42(-0.73%)

Arrowhead Pharmaceuticals, Inc.

ARWR

NASDAQ

$56.55

$0.42(-0.73%)

Chart

Upcoming Earnings

Next report date

May 11, 2026

Report period

Q2 2026

EPS Estimate

$-1.04

Revenue Estimate

$66.56M

Key stats

52-Week Range$56.55

$9.57

$76.76

Market capitalization

$8.03B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

40.99

Basic EPS (TTM)

$1.57

Net income (TTM)

$202.27M

Revenue (TTM)

$1.09B

Avg. volume

2.87M

Beta (1Y)

1.30

Employees

609

Market capitalization

$8.03B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

40.99

Basic EPS (TTM)

$1.57

Net income (TTM)

$202.27M

Revenue (TTM)

$1.09B

Avg. volume

2.87M

Beta (1Y)

1.30

Employees

609

Screener Quick Check

About Arrowhead Pharmaceuticals, Inc.

Sector

Healthcare

Industry

Biotechnology

CEO

Christopher R. Anzalone

Website

arrowheadpharma.com

Headquarters

177 East Colorado Boulevard, Pasadena, CA, 91105

IPO Date

1993-12-16

Identifiers

ISINUS04280A1007

Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The...

Related Stocks

Axsome Therapeutics, Inc.

AXSM

$158.23Mkt Cap: $8.09B

Healthcare

Biotechnology

ISIN:US05464T1043

Vaxcyte, Inc.

PCVX

$55.62Mkt Cap: $8.00B

Healthcare

Biotechnology

ISIN:US92243G1085

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate